Gyre Therapeutics (NASDAQ:GYRE) Stock Price Up 5.5%

Gyre Therapeutics, Inc. (NASDAQ:GYRE)’s share price rose 5.5% during mid-day trading on Friday . The stock traded as high as $13.50 and last traded at $13.30. Approximately 12,811 shares were traded during mid-day trading, a decline of 84% from the average daily volume of 78,800 shares. The stock had previously closed at $12.61.

Gyre Therapeutics Stock Performance

The company’s 50-day moving average price is $12.22 and its 200 day moving average price is $16.05.

Gyre Therapeutics (NASDAQ:GYRE) last announced its quarterly earnings data on Thursday, May 9th. The company reported $0.04 EPS for the quarter. The business had revenue of $27.17 million during the quarter. On average, analysts anticipate that Gyre Therapeutics, Inc. will post -0.45 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Gyre Therapeutics news, Director Nassim Usman sold 3,452 shares of Gyre Therapeutics stock in a transaction on Friday, June 28th. The shares were sold at an average price of $12.00, for a total value of $41,424.00. Following the sale, the director now directly owns 1,636 shares in the company, valued at approximately $19,632. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 2.92% of the stock is owned by company insiders.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.